These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42 related articles for article (PubMed ID: 21794327)
21. High incidence of free monoclonal lambda light chains in the sera of patients with Sjogren's syndrome. Moutsopoulos HM; Steinberg AD; Fauci AS; Lane HC; Papadopoulos NM J Immunol; 1983 Jun; 130(6):2663-5. PubMed ID: 6406594 [TBL] [Abstract][Full Text] [Related]
22. [Sjogren's syndrome]. Rasković S; Bogić M; Perić-Popadić A; Tomić-Spirić V Srp Arh Celok Lek; 1997; 125(1-2):54-8. PubMed ID: 17974357 [TBL] [Abstract][Full Text] [Related]
23. The connective tissue diseases and the overall influence of gender. Lahita RG Int J Fertil Menopausal Stud; 1996; 41(2):156-65. PubMed ID: 8829695 [TBL] [Abstract][Full Text] [Related]
24. Comparison of antinuclear antibody and other immunohematological profiles among primary Sjögren's syndrome, secondary Sjögren's syndrome associated with rheumatoid arthritis or systemic lupus erythematosus, and corresponding systemic disease. Ichikawa Y; Takaya M; Shimizu H; Uchiyama M; Moriuchi J; Morita K; Hoshina Y; Horiki T Tokai J Exp Clin Med; 1993 Dec; 18(3-6):133-8. PubMed ID: 7701526 [TBL] [Abstract][Full Text] [Related]
30. The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. Wallace DJ Lupus; 1996 Jun; 5 Suppl 1():S59-64. PubMed ID: 8803913 [TBL] [Abstract][Full Text] [Related]
31. [Therapy of inflammatory-rheumatic diseases with levamisol, an immunity modulating substance]. Trabert U; Rosenthal M; Müller W Schweiz Med Wochenschr; 1976 Sep; 106(39):1293-301. PubMed ID: 1087457 [TBL] [Abstract][Full Text] [Related]
32. Smoking as a trigger for inflammatory rheumatic diseases. Klareskog L; Padyukov L; Alfredsson L Curr Opin Rheumatol; 2007 Jan; 19(1):49-54. PubMed ID: 17143096 [TBL] [Abstract][Full Text] [Related]
33. Diagnostic, prognostic and therapeutic aspects of systemic lupus erythematosus and rheumatoid arthritis. Weyand C Klin Wochenschr; 1990; 68 Suppl 21():55-63. PubMed ID: 2198390 [TBL] [Abstract][Full Text] [Related]
36. [Therapeutic apheresis for rheumatic diseases]. Yamaji K Nihon Rinsho; 2009 Mar; 67(3):606-11. PubMed ID: 19280940 [TBL] [Abstract][Full Text] [Related]
37. The association of malignancy with rheumatic and connective tissue diseases. Carsons S Semin Oncol; 1997 Jun; 24(3):360-72. PubMed ID: 9208890 [TBL] [Abstract][Full Text] [Related]
38. Psychological aspects of rheumatic diseases. Ng LL Singapore Med J; 1992 Feb; 33(1):79-81. PubMed ID: 1598613 [TBL] [Abstract][Full Text] [Related]
39. Main Oral Manifestations in Immune-Mediated and Inflammatory Rheumatic Diseases. Gualtierotti R; Marzano AV; Spadari F; Cugno M J Clin Med; 2018 Dec; 8(1):. PubMed ID: 30585183 [TBL] [Abstract][Full Text] [Related]
40. [Antimalarials: an update in rheumatic diseases]. Jiménez Palop M Reumatol Clin; 2006 Jul; 2(4):190-201. PubMed ID: 21794327 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]